Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

Oncotarget - 6 Oct 2015

Caiola Elisa, Salles Daniela, Frapolli Roberta, Lupi Monica, Rotella Giuseppe, Ronchi Anna, Garassino Marina Chiara, Mattschas Nikola, Colavecchio Stefano, Broggini Massimo, Wiesmüller Lisa, Marabese Mirko

Abstract excerpt

KRAS mutations in NSCLC are supposed to indicate a poor prognosis and poor response to anticancer treatments but this feature lacks a mechanistic basis so far. In tumors, KRAS was found to be mutated mostly at codons 12 and 13 and a pool of mutations differing in the base alteration and the amino acid substitution have been described. The different KRAS mutations may differently impact on cancerogenesis and drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cation Transport Proteins
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Mice, Nude

Share to Microscopy, Fluorescence

Share to NIH 3T3 Cells

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26353932
DOI: 10.18632/oncotarget.5019
PMCID: PMC4745782

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.PMID 26353932Read ↗

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.Semantic proximity Read ↗

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.Semantic proximity Read ↗

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.Semantic proximity Read ↗

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Semantic proximity Read ↗

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.Semantic proximity Read ↗

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Semantic proximity Read ↗

Across the universe of K-RAS mutations in non-small-cell-lung cancer.Semantic proximity Read ↗

KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer.Semantic proximity Read ↗

KRAS codon 12 mutations in Australian non-small cell lung cancer.Semantic proximity Read ↗

Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.Semantic proximity Read ↗

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.Semantic proximity Read ↗

Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.